Literature DB >> 30323087

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.

Gregory P Kalemkerian, Billy W Loo, Wallace Akerley, Albert Attia, Michael Bassetti, Yanis Boumber, Roy Decker, M Chris Dobelbower, Afshin Dowlati, Robert J Downey, Charles Florsheim, Apar Kishor P Ganti, John C Grecula, Matthew A Gubens, Christine L Hann, James A Hayman, Rebecca Suk Heist, Marianna Koczywas, Robert E Merritt, Nisha Mohindra, Julian Molina, Cesar A Moran, Daniel Morgensztern, Saraswati Pokharel, David C Portnoy, Deborah Rhodes, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Charles C Williams, Karin G Hoffmann, Miranda Hughes.   

Abstract

The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for SCLC regarding immunotherapy, systemic therapy, and radiation therapy. For the 2018 update, new sections were added on "Signs and Symptoms of SCLC" and "Principles of Pathologic Review."
Copyright © 2018 by the National Comprehensive Cancer Network.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30323087     DOI： 10.6004/jnccn.2018.0079

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  62 in total

1.  Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?

Authors:  Francesco Passiglia; Silvia Novello
Journal:  Ann Transl Med       Date:  2018-12

2.  Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome.

Authors:  Richard Thomas; Yu-Hui Chen; Hiroto Hatabu; Raymond H Mak; Mizuki Nishino
Journal:  Lung Cancer       Date:  2020-04-30       Impact factor: 5.705

Review 3.  Small-cell lung cancer.

Authors:  Charles M Rudin; Elisabeth Brambilla; Corinne Faivre-Finn; Julien Sage
Journal:  Nat Rev Dis Primers       Date:  2021-01-14       Impact factor: 52.329

4.  First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.

Authors:  Shen Lin; Shaohong Luo; Dian Gu; Meiyue Li; Xin Rao; Changlian Wang; Pinfang Huang; Xiongwei Xu; Xiuhua Weng
Journal:  Oncologist       Date:  2021-09-12

5.  Prophylactic cranial irradiation is associated with improved survival following resection for limited stage small cell lung cancer.

Authors:  Benjamin J Resio; Jessica Hoag; Alexander Chiu; Andres Monsalve; Andrew P Dhanasopon; Daniel J Boffa; Justin D Blasberg
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

6.  pN1 but not pN0/N2 predicts survival benefits of prophylactic cranial irradiation in small-cell lung cancer patients after surgery.

Authors:  Haitang Yang; Mohammad Faisal Al-Hurani; Jianlin Xu; Liwen Fan; Ralph A Schmid; Heng Zhao; Feng Yao
Journal:  Ann Transl Med       Date:  2021-04

7.  Predictors of survival following surgical resection of limited-stage small cell lung cancer.

Authors:  Nicolas Zhou; Matthew Bott; Bernard J Park; Eric Vallières; Candice L Wilshire; Kazuhiro Yasufuku; Jonathan D Spicer; David R Jones; Boris Sepesi
Journal:  J Thorac Cardiovasc Surg       Date:  2020-11-27       Impact factor: 5.209

8.  Small cell carcinoma of the bladder: A population-based analysis of long-term outcomes after radical cystectomy and bladder conservation with chemoradiotherapy.

Authors:  Justin Oh; Bernhard Eigl; Peter C Black; Tom Pickles; Carlos Villamil; Katherine Sunderland; Scott Tyldesley
Journal:  Can Urol Assoc J       Date:  2022-02       Impact factor: 1.862

9.  FDG PET/CT in the Staging of Lung Cancer.

Authors:  Mohsen Farsad
Journal:  Curr Radiopharm       Date:  2020

10.  Extensive-disease small cell lung cancer, multiple relapses, five lines of therapy and more than 10-year survival.

Authors:  Pawan Kumar Singh; Deepa Kumari Shrestha; Navneet Singh; Nalini Gupta
Journal:  BMJ Case Rep       Date:  2020-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.